ASTRAZENECA FILES ZOMIG® NASAL SPRAY IN EUROPE
AstraZeneca announced today that it has submitted its first regulatory application in Europe for Zomig (zolmitriptan) Nasal Spray for the acute treatment of migraine with or without aura. This new treatment will be reviewed under the Mutual Recognition procedure with Sweden acting as the reference member state. This is the first filing of a second-generation triptan for a nasal spray formulation. Zomig Nasal Spray 5 mg offers migraine sufferers several key benefits in terms of speed of onset combined with high efficacy and good tolerability without the need for injection. It can be used anytime a migraine attack strikes, and is effective when taken at anytime during the migraine headache. It is especially useful in patients with nausea and vomiting, is consistently effective and is even effective against the majority of severe attacks. "Migraine sufferers have varying needs and no single migraine treatment meets all patients' requirements. With our portfolio of Zomig formulations - oral tablets, Zomig Rapimelt and Nasal Spray - doctors will be able to effectively treat a very wide range of patients, and patients can select the formulation which they prefer", said Geoff Birkett, Vice President, AstraZeneca CNS (Central Nervous System). Launched throughout the US and Europe Zomig is the leading second-generation triptan with 1999 sales of approximately $200 million.
Other news from the department
